News

For decades, the standard first-line treatment for Acute Myeloid Leukemia has been the intensive “7+3” chemotherapy regimen, which combines cytarabine with an anthracycline drug. However, experts such as Richard Stone say the dominance of this approach is gradually fading as new targeted and less toxic therapies become available. One major challenger is the combination of

The Phase III STELLAR trial found that combining Eflornithine with Lomustine significantly improves outcomes for patients with recurrent IDH-mutant Grade 3 Astrocytoma, an aggressive type of brain tumor. While the combination did not benefit the entire study population, patients in this specific molecular subgroup saw median overall survival increase from 23.5 months with lomustine alone

Researchers have developed a new targeted nanomedicine that combines chemotherapy and immunotherapy to treat Colorectal Cancer. The therapy uses irinotecan loaded into nanoparticles coated with molecules that specifically bind to CD44v6, a protein commonly found on metastatic colorectal cancer cells. This approach allows the chemotherapy to reach tumors more precisely while boosting the immune system

Long-term results from the CheckMate 9ER trial show that deeper tumor shrinkage is strongly linked to longer survival in patients with advanced Renal Cell Carcinoma treated with a combination of Cabozantinib (Cabometyx) and Nivolumab (Opdivo). The findings, presented in early 2026, come from a long-term follow-up of about 67 months. Researchers found that patients who